This signalling pathway is involved in the development and progression of many cancers, including prostate cancer,27 bladder cancer,28 ovarian cancer29 and breast cancer.30 However, the regulators of the AKT–MDM2–p53 pathway in ESCC are poorly understood. This evidence concerns the gene MDM2 and urinary bladder carcinoma.